Mary Frances McMullin

List of Publications by Citations

230 papers	9,225 citations	47 h-index	92 g-index
237 ext. papers	10,487 ext. citations	5.1 avg, IF	5.71 L-index

#	Paper	IF	Citations
230	JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. *New England Journal of Medicine*, **2007**, 356, 459-68	59.2	996
229	Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. *Journal of Clinical Oncology*, **2011**, 29, 761-70	2.2	589
228	A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. *Cancer*, **2007**, 109, 1114-24	6.4	478
227	Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2015**, 16, 1295-305	21.7	316
226	Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. *British Journal of Haematology*, **2005**, 130, 174-95	4.5	264
225	A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 654-9	11.5	263
224	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. *New England Journal of Medicine*, **2018**, 379, 1416-1430	59.2	256
223	A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. *New England Journal of Medicine*, **2008**, 358, 162-8	59.2	247
222	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. *Nature Genetics*, **2015**, 47, 717-726	36.3	244
221	Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. *Blood*, **2010**, 115, 2891-900	2.2	224
220	Guideline for investigation and management of adults and children presenting with a thrombocytosis. *British Journal of Haematology*, **2010**, 149, 352-75	4.5	209
219	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. *Blood*, **2009**, 113, 4829-33	2.2	193
218	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. *Blood*, **2013**, 121, 4778-81	2.2	159
217	Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. *Blood*, **2011**, 117, 2813-6	2.2	153
216	Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. *PLoS Medicine*, **2006**, 3, e290	11.6	145
215	A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. *Blood*, **2007**, 110, 2193-6	2.2	128
214	The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. *Leukemia*, **2013**, 27, 75-81	10.7	127

213	Regulation of human metabolism by hypoxia-inducible factor. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 12722-7	11.5	122
212	Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. *Blood*, **2013**, 122, 1384-94	2.2	109
211	The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. *Blood*, **2007**, 109, 4924-9	2.2	104
210	Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. *Blood*, **2017**, 130, 1889-1897	2.2	101
209	How common are myeloproliferative neoplasms? A systematic review and meta-analysis. *American Journal of Hematology*, **2014**, 89, 581-7	7.1	97
208	Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. *Blood*, **2008**, 111, 5400-2	2.2	96
207	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. *Haematologica*, **2016**, 101, 926-31	6.6	91
206	Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. *British Journal of Haematology*, **2007**, 138, 821-2	4.5	90
205	Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry. *Blood*, **2003**, 102, 1097-9	2.2	85
204	Genetic basis of congenital erythrocytosis: mutation update and online databases. *Human Mutation* , **2014**, 35, 15-26	4.7	82
203	JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. *Blood*, **2012**, 120, 2704-7	2.2	81
202	The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. *Blood*, **2010**, 115, 4517-23	2.2	80
201	Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. *Leukemia*, **2013**, 27, 2032-9	10.7	78
200	Guideline for the diagnosis and management of myelofibrosis. *British Journal of Haematology*, **2012** , 158, 453-71	4.5	76
199	Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. *British Journal of Haematology*, **2009**, 144, 904-8	4.5	72
198	Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2alpha gain-of-function mutation. *FASEB Journal*, **2011**, 25, 2001-11	0.9	72
197	The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. *Haematologica*, **2007**, 92, 1607-14	6.6	70
196	Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. *British Journal of Haematology*, **2013**, 160, 25-34	4.5	68

195	The classification and diagnosis of erythrocytosis. *International Journal of Laboratory Hematology*, **2008**, 30, 447-59	2.5	65
194	Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. *Leukemia*, **2013**, 27, 843-51	10.7	63
193	Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation. *Bone Marrow Transplantation*, **2014**, 49, 42-8	4.4	62
192	The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. *Blood*, **2004**, 103, 1937-40	2.2	61
191	A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. *British Journal of Haematology*, **2019**, 184, 176-191	4.5	60
190	A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. *British Journal of Haematology*, **2013**, 162, 498-508	4.5	58
189	Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature. *Clinical Cancer Research*, **2017**, 23, 6430-6440	12.9	56
188	Molecular diagnostics of myeloproliferative neoplasms. *European Journal of Haematology*, **2015**, 95, 270-88	3.8	56
187	Global down-regulation of HOX gene expression in PML-RARalpha + acute promyelocytic leukemia identified by small-array real-time PCR. *Blood*, **2003**, 101, 1558-65	2.2	54
186	The diagnosis and management of erythrocytosis. *BMJ, The*, **2013**, 347, f6667	5.9	48
185	Erythrocytosis-associated HIF-2alpha mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor proline. *Journal of Biological Chemistry*, **2009**, 284, 9050-8	5.4	47
184	A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline. *British Journal of Haematology*, **2019**, 184, 161-175	4.5	47
183	A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylation. *Molecular Cancer*, **2003**, 2, 31	42.1	45
182	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. *Leukemia*, **2019**, 33, 1996-2005	10.7	43
181	Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations. *Haematologica*, **2016**, 101, 1306-1318	6.6	43
180	Erythrocytosis due to a mutation in the erythropoietin receptor gene. *British Journal of Haematology*, **1998**, 100, 407-10	4.5	41
179	Familial idiopathic methemoglobinemia revisited: original cases reveal 2 novel mutations in NADH-cytochrome b5 reductase. *Blood*, **2002**, 100, 3447-9	2.2	39
178	Identification of high oxygen affinity hemoglobin variants in the investigation of patients with erythrocytosis. *Haematologica*, **2009**, 94, 1321-2	6.6	37

177	The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. *Journal of Translational Medicine*, **2018**, 16, 360	8.5	36
176	Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. *British Journal of Haematology*, **2013**, 160, 188-98	4.5	35
175	Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions. *Journal of Clinical Investigation*, **2013**, 123, 2169-82	15.9	35
174	Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. *Leukemia*, **2017**, 31, 882-888	10.7	33
173	Idiopathic erythrocytosis: a disappearing entity. *Hematology American Society of Hematology Education Program*, **2009**, 629-35	3.1	33
172	Haemoglobin during pregnancy: relationship to erythropoietin and haematinic status. *European Journal of Haematology*, **2003**, 71, 44-50	3.8	33
171	Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. *American Journal of Hematology*, **2012**, 87, 175-82	7.1	32
170	Two new mutations in the HIF2A gene associated with erythrocytosis. *American Journal of Hematology*, **2012**, 87, 439-42	7.1	32
169	The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. *Experimental Hematology and Oncology*, **2015**, 4, 26	7.8	32
168	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). *Blood*, **2018**, 132, 577-577	2.2	32
167	Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. *Journal of Clinical Oncology*, **2018**, 36, 3361-3369	2.2	32
166	Low-dose thalidomide in myelofibrosis. *Haematologica*, **2008**, 93, 1100-1	6.6	31
165	Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. *British Journal of Haematology*, **2014**, 167, 421-3	4.5	30
164	Community-acquired infections and their association with myeloid malignancies. *Cancer Epidemiology*, **2014**, 38, 56-61	2.8	30
163	Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. *British Journal of Haematology*, **2014**, 167, 418-20	4.5	30
162	Comparison of the mouse spleen cell assay and a radioimmunoassay for the measurement of serum erythropoietin. *British Journal of Haematology*, **1988**, 70, 117-20	4.5	30
161	Clinical and hematological presentation of children and adolescents with polycythemia vera. *Annals of Hematology*, **2009**, 88, 713-9	3	29
160	The V617F JAK2 mutation and the myeloproliferative disorders. *Hematological Oncology*, **2005**, 23, 91-3	1.3	29

159	Homocysteine and methylmalonic acid as indicators of folate and vitamin B12 deficiency in pregnancy. *International Journal of Laboratory Hematology*, **2001**, 23, 161-5		28
158	HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy. *Haematologica*, **2013**, 98, 1216-25	6.6	27
157	The role of PHD2 mutations in the pathogenesis of erythrocytosis. *Hypoxia (Auckland, N Z)*, **2014**, 2, 71-90	2.1	26
156	Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation. *British Journal of Haematology*, **2014**, 166, 800-2	4.5	26
155	HIF pathway mutations and erythrocytosis. *Expert Review of Hematology*, **2010**, 3, 93-101	2.8	26
154	Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera. *British Journal of Haematology*, **2008**, 142, 622-6	4.5	26
153	Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. *American Journal of Hematology*, **2015**, 90, 864-70	7.1	24
152	A nonsynonymous LNK polymorphism associated with idiopathic erythrocytosis. *American Journal of Hematology*, **2011**, 86, 962-4	7.1	24
151	Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. *Heart*, **2009**, 95, 1225-9	5.1	24
150	LNK mutations and myeloproliferative disorders. *American Journal of Hematology*, **2016**, 91, 248-51	7.1	24
149	Investigation and Management of Erythrocytosis. *Current Hematologic Malignancy Reports*, **2016**, 11, 342-7	4.4	23
148	The molecular basis of disorders of red cell enzymes. *Journal of Clinical Pathology*, **1999**, 52, 241-4	3.9	23
147	Erythrocytosis in children and adolescents-classification, characterization, and consensus recommendations for the diagnostic approach. *Pediatric Blood and Cancer*, **2013**, 60, 1734-8	3	21
146	Chromosomal abnormalities in Ph- cells of patients on imatinib. *Blood*, **2003**, 102, 2700-1; author reply 2701	2.2	21
145	Epigenetics in Myeloproliferative Neoplasms. *Journal of Cellular and Molecular Medicine*, **2017**, 21, 1660-1667	5.6	20
144	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. *Blood*, **2016**, 128, 479-479	2.2	20
143	Second cancers in MPN: Survival analysis from an international study. *American Journal of Hematology*, **2020**, 95, 295-301	7.1	20
142	Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. *Leukemia*, **2020**, 34, 2234-2237	10.7	19

141	SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. *Haematologica*, **2009**, 94, 576-80	6.6	19
140	Diagnosis and management of congenital and idiopathic erythrocytosis. *Therapeutic Advances in Hematology*, **2012**, 3, 391-8	5.7	19
139	Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?. *British Journal of Haematology*, **2012**, 157, 426-37	4.5	18
138	Epidemiology of MPN: what do we know?. *Current Hematologic Malignancy Reports*, **2014**, 9, 340-9	4.4	18
137	Anthracycline cardiotoxicity. *European Heart Journal*, **2006**, 27, 1137-8	9.5	18
136	Management of polycythaemia vera: a critical review of current data. *British Journal of Haematology*, **2016**, 172, 337-49	4.5	18
135	The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. *Haematologica*, **2006**, 91, 413-4	6.6	18
134	The molecular basis of disorders of the red cell membrane. *Journal of Clinical Pathology*, **1999**, 52, 245-8	3.9	16
133	JAK2 V617F: a single mutation in the myeloproliferative group of disorders. *Ulster Medical Journal*, **2006**, 75, 112-9	0.4	16
132	Low Dose Ara-C Versus Hydroxyurea with or without Retinoid in Older Patients Not Considered Fit for Intensive Chemotherapy: The UK NCRI AML14 Trial.. *Blood*, **2004**, 104, 872-872	2.2	15
131	Erythrocytosis associated with a novel missense mutation in the BPGM gene. *Haematologica*, **2014**, 99, e201-4	6.6	14
130	Proteasome proteolytic profile is linked to Bcr-Abl expression. *Experimental Hematology*, **2009**, 37, 357-66	3.1	14
129	Molecular mechanisms of drug resistance in acute myeloid leukaemia. *Expert Opinion on Drug Metabolism and Toxicology*, **2007**, 3, 363-77	5.5	14
128	The therapeutic potential of the proteasome in leukaemia. *Hematological Oncology*, **2008**, 26, 73-81	1.3	14
127	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. *Blood*, **2020**, 135, 381-386	2.2	14
126	Lack of association of the heparanase gene single-nucleotide polymorphism Arg307Lys with acute lymphoblastic leukaemia in patients from Northern Ireland. *Leukemia*, **2008**, 22, 1629-31; discussion 1631-3	10.7	13
125	Oxygen sensing: recent insights from idiopathic erythrocytosis. *Cell Cycle*, **2006**, 5, 941-5	4.7	13
124	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. *Blood*, **2013**, 122, 394-394	2.2	13

123	Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms. *HemaSphere*, **2020**, 4, e327	0.3	12
122	Sequence analysis of the 3' hypoxia-responsive element of the human erythropoietin gene in patients with erythrocytosis. *Biochemical and Molecular Medicine*, **1997**, 62, 132-4		12
121	Mutation of the von Hippel-Lindau gene alters human cardiopulmonary physiology. *Advances in Experimental Medicine and Biology*, **2008**, 605, 51-6	3.6	12
120	Protein tyrosine phosphatase receptor type C (PTPRC or CD45). *Journal of Clinical Pathology*, **2021**, 74, 548-552	3.9	12
119	Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response. *Leukemia Research*, **2014**, 38, 310-5	2.7	11
118	Acute intestinal obstruction due to intramural haemorrhage in small intestine in a patient with severe haemophilia A and inhibitor. *European Journal of Haematology*, **2005**, 75, 164-6	3.8	11
117	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. *Future Oncology*, **2021**, 17, 1449-1458	3.6	11
116	Polycythaemia-inducing mutations in the erythropoietin receptor (EPOR): mechanism and function as elucidated by epidermal growth factor receptor-EPOR chimeras. *British Journal of Haematology*, **2014**, 165, 519-28	4.5	10
115	Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. *Leukemia Research*, **2014**, 38, 816-21	2.7	10
114	Secondary erythrocytosis. *Hematology*, **2014**, 19, 183-4	2.2	10
113	Clinical utility gene card for: familial erythrocytosis. *European Journal of Human Genetics*, **2012**, 20,	5.3	10
112	Molecular pathogenesis of the myeloproliferative neoplasms. *Journal of Hematology and Oncology*, **2021**, 14, 103	22.4	10
111	Congenital erythrocytosis. *International Journal of Laboratory Hematology*, **2016**, 38 Suppl 1, 59-65	2.5	10
110	The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. *Blood*, **2019**, 134, 2107-2111	2.2	9
109	Clinical utility gene card for: hereditary thrombocythemia. *European Journal of Human Genetics*, **2014**, 22,	5.3	8
108	Dramatic resolution of respiratory symptoms with imatinib mesylate in patients with chronic myeloid leukemia presenting with lower airway symptoms resembling asthma. *Leukemia and Lymphoma*, **2009**, 50, 1721-2	1.9	8
107	Pyruvate kinase deficient hemolytic anemia in the Northern Irish population. *Blood Cells, Molecules, and Diseases*, **2007**, 39, 189-94	2.1	8
106	Genotyping of thiopurine methyltransferase in patients with acute leukemia using LightCycler PCR. *Leukemia and Lymphoma*, **2006**, 47, 1624-8	1.9	8

105	Erythropoietin receptor and hematological disease. *American Journal of Hematology*, **1999**, 60, 55-60	7.1	8
104	Protein deregulation associated with breast cancer metastasis. *Cytokine and Growth Factor Reviews* , **2015**, 26, 415-23	17.9	7
103	HFE mutations in idiopathic erythrocytosis. *British Journal of Haematology*, **2018**, 181, 270-272	4.5	7
102	Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients. *Hematology*, **2008**, 13, 133-6	2.2	7
101	A review of the therapeutic agents used in the management of polycythaemia vera. *Hematological Oncology*, **2007**, 25, 58-65	1.3	7
100	Comparison of diagnostic criteria for polycythaemia vera. *Hematology*, **2007**, 12, 123-30	2.2	7
99	The optimal management of polycythaemia vera. *British Journal of Haematology*, **2003**, 120, 543-4; author reply 544-5	4.5	7
98	Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials. *Blood*, **2013**, 122, 358-358	2.2	7
97	Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. *Journal of Clinical Oncology*, **2021**, 39, 890-901	2.2	7
96	The Calreticulin gene and myeloproliferative neoplasms. *Journal of Clinical Pathology*, **2016**, 69, 841-5	3.9	7
95	Integration of conventional cytogenetics, comparative genomic hybridisation and interphase fluorescence in situ hybridisation for the detection of genomic rearrangements in acute leukaemia. *Journal of Clinical Pathology*, **2008**, 61, 903-8	3.9	6
94	A Randomized, Phase 3, Trial of Interferon- versus Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia.. *Blood*, **2022**,	2.2	6
93	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. *Blood*, **2018**, 132, 3032-3032	2.2	6
92	The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF).. *Blood*, **2012**, 120, 2838-2838	2.2	6
91	Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm. *Leukemia*, **2021**, 35, 2424-2430	10.7	6
90	Splanchnic venous thrombosis in V617F mutation positive myeloproliferative neoplasms - long term follow-up of a regional case series. *Thrombosis Journal*, **2018**, 16, 33	5.6	6
89	Somatic mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemia. *Journal of Clinical Pathology*, **2019**, 72, 778-782	3.9	5
88	Facing erythrocytosis: Results of an international physician survey. *American Journal of Hematology*, **2019**, 94, E225-E227	7.1	5

87	Aetiology of Myeloproliferative Neoplasms. *Cancers*, **2020**, 12,	6.6	5
86	Diagnostic pathway for the investigation of thrombocytosis. *British Journal of Haematology*, **2013**, 161, 604-6	4.5	5
85	Characteristics and outcomes of haematology patients admitted to the intensive care unit. *Nursing in Critical Care*, **2013**, 18, 193-9	2.7	5
84	Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation. *Haematologica*, **2009**, 94, 296-8	6.6	5
83	Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. *British Journal of Haematology*, **2021**, 192, 62-74	4.5	5
82	Expand: a Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis and Baseline Platelet Counts Between 50 □109/L and 99 □109/L. *Blood*, **2012**, 120, 177-177	2.2	5
81	Diagnostic workflow for hereditary erythrocytosis and thrombocytosis. *Hematology American Society of Hematology Education Program*, **2019**, 2019, 391-396	3.1	5
80	Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. *Blood Cancer Journal*, **2021**, 11, 53	7	5
79	Significance of NPM1 Gene Mutations in AML. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
78	Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. *Experimental Hematology*, **2019**, 79, 26-34	3.1	4
77	The MOSAICC study: Assessing feasibility for biological sample collection in epidemiology studies and comparison of DNA yields from saliva and whole blood samples. *Annals of Human Genetics*, **2018**, 82, 114-118	2.2	4
76	Management of newly diagnosed chronic myeloid leukaemia during a twin pregnancy using leucapheresis: Case report and review of the literature. *Transfusion and Apheresis Science*, **2015**, 52, 199-203	2.4	4
75	Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings. *Blood*, **2019**, 134, 2943-2943	2.2	4
74	Modification or Dose or Treatment Duration Has No Impact on Outcome of AML in Older Patients: Preliminary Results of the UK NCRI AML14 Trial.. *Blood*, **2005**, 106, 543-543	2.2	4
73	The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 Pick a Winner Comparison. *Blood*, **2010**, 116, 18-18	2.2	4
72	Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR.. *Blood*, **2010**, 116, 3427-3427	2.2	4
71	A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia. *Blood*, **2012**, 120, 803-803	2.2	4
70	A Two-Part Study of Givinostat in Patients with Polycythemia Vera: Maximum Tolerated Dose Definition and Preliminary Efficacy Results. *Blood*, **2016**, 128, 4261-4261	2.2	4

69	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. *Blood*, **2016**, 128, 4271-4271	2.2	4
68	The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms. *International Journal of Laboratory Hematology*, **2016**, 38, 102-6	2.5	3
67	Outcomes of pregnancy in patients with congenital erythrocytosis. *British Journal of Haematology*, **2015**, 170, 586-8	4.5	3
66	Tumour lysis syndrome after splenic irradiation in a patient with JAK2 V617F post-polycythaemia vera myelofibrosis. *Clinical Oncology*, **2010**, 22, 893	2.8	3
65	Is congenital secondary erythrocytosis/polycythemia caused by activating mutations within the HIF-2 alpha iron-responsive element?. *Blood*, **2007**, 110, 2776-7	2.2	3
64	Survival from Acute MyeloidLeukaemia in Patients Over 55 Years of Age in Northern Ireland: A Discrete Population. *Hematology*, **2001**, 6, 103-10	2.2	3
63	Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study. *Blood*, **2020**, 136, 33-35	2.2	3
62	Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial. *Blood*, **2016**, 128, 1065-1065	2.2	3
61	Genetic Background of Congenital Erythrocytosis. *Genes*, **2021**, 12,	4.2	3
60	Acute promyelocytic leukaemia (APML) with cryptic PML-RARA fusion has a clinical course comparable to classical APML with t(15;17)(q24.1;q21.2) translocation. *British Journal of Haematology*, **2019**, 186, 155-157	4.5	3
59	Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. *Leukemia*, **2021**, 35, 1197-1202	10.7	3
58	Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort. *Journal of Clinical Pathology*, **2021**, 74, 808-811	3.9	2
57	The finding of a reciprocal whole-arm translocation t(X;12)(p10;p10) in association with atypical chronic myeloid leukaemia. *Medical Oncology*, **2010**, 27, 760-2	3.7	2
56	Molecular and Clinical Features of the Myeloproliferative Neoplasm Associated with JAK2 Exon 12 Mutations: a European Multicenter Study.. *Blood*, **2009**, 114, 3904-3904	2.2	2
55	A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m2 and 6mg/m2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial. *Blood*, **2014**, 124, 2308-2308	2.2	2
54	(32)P in the treatment of myeloproliferative disorders. *Ulster Medical Journal*, **2016**, 85, 83-5	0.4	2
53	Equivalence of BCSH and WHO diagnostic criteria for ET. *Leukemia*, **2017**, 31, 527-528	10.7	1
52	Absence of CALR Mutations in Idiopathic Erythrocytosis Patients with Low Serum Erythropoietin Levels. *Acta Haematologica*, **2018**, 139, 217-219	2.7	1

51	Patient perspectives of a diagnosis of myeloproliferative neoplasm in a case control study. *Experimental Hematology and Oncology*, **2015**, 5, 14	7.8	1
50	A novel base change leading to Hb Vanderbilt [89(F5)Ser->Arg, AGT>AGA]. *Hemoglobin*, **2011**, 35, 428-9	0.6	1
49	Commentary. *Clinical Chemistry*, **2012**, 58, 335	5.5	1
48	Management of myelofibrosis: a survey of current practice in the United Kingdom. *Journal of Clinical Pathology*, **2012**, 65, 1124-7	3.9	1
47	Reply to Ostrovosky et al.. *Leukemia*, **2008**, 22, 1632-1632	10.7	1
46	G-CSF increases proteasome activity in myeloid cells. *British Journal of Haematology*, **2008**, 143, 598-601	4.5	1
45	Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms. *Blood*, **2018**, 132, 4279-4279	2.2	1
44	Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. *Blood*, **2019**, 134, 4170-4170	2.2	1
43	Erythrocytosis Caused by Mutations in the PHD2 and VHL Genes.. *Blood*, **2007**, 110, 3663-3663	2.2	1
42	HIF-2alpha Associated Familial Erythrocytosis Supports the PHD2-HIF- 2alpha-VHL Axis as the Major Regulator of Erythropoietin Production. *Blood*, **2008**, 112, 481-481	2.2	1
41	Symptom Burden Among PV and ET Patients Receiving A Novel Histone Deacetylase Inhibitor: Findings From a Open-Label Phase II Study. *Blood*, **2012**, 120, 1736-1736	2.2	1
40	A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML. *Blood*, **2012**, 120, 889-889	2.2	1
39	Assessment and Validation of the EQ-5D Among a Population of Myeloproliferative Neoplasm Patients. *Blood*, **2015**, 126, 5179-5179	2.2	1
38	Analysis of HOXA5 and HOXB3 Expression Complements Conventional Cytogenetic Analysis in Acute Myeloid Leukemia.. *Blood*, **2007**, 110, 2388-2388	2.2	1
37	Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial. *Blood*, **2018**, 132, 1762-1762	2.2	1
36	Myeloproliferative Neoplasms: An in-Depth Case-Control (MOSAICC) Study. *Blood*, **2015**, 126, 1621-1621	2.2	1
35	A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial. *Blood*, **2015**, 126, 221-221	2.2	1
34	A molecular diagnostic algorithm for JAK2 V617F investigations in suspected myeloproliferative neoplasms. *Irish Journal of Medical Science*, **2020**, 189, 621-626	1.9	1

33	Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms. *Cancers*, **2020**, 12,	6.6	1
32	Hereditary thrombocytosis: the genetic landscape. *British Journal of Haematology*, **2021**, 194, 1098-1105	4.5	1
31	A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment **2007**, 109, 1114		1
30	Experience of Myeloproliferative Neoplasms Guidelines in the United Kingdom: Perspective and International Context. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, e1626-e1631	7.3	
29	Minor allele frequency of myeloproliferative neoplasm mutations in the Irish blood donor population. *Hematological Oncology*, **2016**, 34, 161-4	1.3	
28	A Japanese Family with Congenital Erythrocytosis Caused by Haemoglobin Bethesda. *Internal Medicine*, **2015**, 54, 2389-93	1.1	
27	Update in the myeloproliferative neoplasms. *Clinical Medicine*, **2014**, 14 Suppl 6, s66-70	1.9	
26	British Society of Haematology, Slide Session presented at the Annual Scientific Meeting, Brighton 2009. *International Journal of Laboratory Hematology*, **2010**, 32, 616-24	2.5	
25	Hepatosplenic Candidiasis, its Treatment and Effect on Remission Status in Patients with Acute Leukaemia-a Report of Five Cases. *Hematology*, **2001**, 6, 331-5	2.2	
24	Prevention of Infection after Splenectomy. *BioDrugs*, **1995**, 3, 191-195		
23	Presidential address to the Ulster Medical Society on 3rd October 2019. *Ulster Medical Journal*, **2020**, 89, 72-76	0.4	
22	Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera. *Blood*, **2021**, 138, 3644-3644	2.2	
21	A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial. *Blood*, **2021**, 138, 2355-2355	2.2	
20	Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study. *Blood*, **2021**, 138, 1507-1507	2.2	
19	Artificial Neural Network Analysis of HOX Gene Expression Profiles Predicts Prognostic Subgroups in Acute Myeloid Leukemia.. *Blood*, **2006**, 108, 2318-2318	2.2	
18	Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide. *Blood*, **2018**, 132, 3037-3037	2.2	
17	Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study. *Blood*, **2018**, 132, 1784-1784	2.2	
16	Myeloproliferative Neoplasms in Patients below 25 Years Old at Diagnosis: A Retrospective International Cooperative Work. *Blood*, **2018**, 132, 1759-1759	2.2	

15	Myeloproliferative Neoplasm Patient Symptom Burden and Quality of Life: Evidence of Significant Impairment Compared to Controls Using Multivariate Analysis. *Blood*, **2015**, 126, 1620-1620	2.2
14	Conditional Deletion of the Hoxa Cluster in MLL-AF9 Is Incompatible with Leukemia Maintenance. *Blood*, **2015**, 126, 3630-3630	2.2
13	Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia. *Blood*, **2016**, 128, 1929-1929	2.2
12	Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Interim Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial. *Blood*, **2016**, 128, 5479-5479	2.2
11	Low Dose Ara-C Versus Low Dose Ara-C and Arsenic Trioxide: the UK NCRI AML16 Pick a Winner Comparison.. *Blood*, **2009**, 114, 486-486	2.2
10	SOCS3 Phosphorylation In Myeloproliferative Neoplasms. *Blood*, **2010**, 116, 3083-3083	2.2
9	Increased MSI2 expression Is Associated with Aggressive CML and AML. *Blood*, **2011**, 118, 2516-2516	2.2
8	First Achievements of MPN&MPNr-EuroNet (COST Action BM0902), a New European Network Dedicated to the Diagnosis of Myeloproliferative Neoplasms and Hereditary Erythrocytosis and Thrombocytosis. *Blood*, **2011**, 118, 2809-2809	2.2
7	Critical Issues About the Diagnosis of Myeloproliferative Neoplasms: World Health Organization Classification **2012**, 37-45	
6	Polycythemia-Inducing Mutations In The Erythropoietin Receptor (EPOR): Mechanism and Function Elucidated By EGFR EPOR Chimeras. *Blood*, **2013**, 122, 2174-2174	2.2
5	Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis1-8	
4	Coexistence of inversion 16 in chronic myeloid leukaemia in blast crisis. *Journal of Hematopathology* , **2016**, 9, 155-160	0.4
3	Reducing the burden of MPN. *Blood*, **2019**, 134, 1483-1484	2.2
2	Ruxolitinib: gaining more than intended. *Blood*, **2020**, 135, 983-984	2.2
1	A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective. *Expert Review of Hematology*, **2018**, 11, 25-35	2.8